DelveInsight’s “Multiple System Atrophy Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple System Atrophy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Multiple System Atrophy Pipeline? @ Multiple System Atrophy Pipeline Outlook Report
Key Takeaways from the Multiple System Atrophy Pipeline Report
Want to know which companies are leading innovation in Multiple System Atrophy? @ Multiple System Atrophy Clinical Trials Assessment
The Multiple System Atrophy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Multiple System Atrophy Pipeline Report also highlights the unmet needs with respect to the Multiple System Atrophy.
Multiple System Atrophy Overview
Multiple system atrophy (MSA) is a rare disease, affecting potentially 15,000 to 50,000 Americans, including people of all racial groups. The cause of MSA is unknown. The vast majority of cases are sporadic, meaning they occur at random. Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the central nervous system (which controls how a person moves), and the autonomic nervous system, which controls involuntary functions such as blood pressure or digestion.
Multiple System Atrophy Emerging Drugs Profile
Amlenetug (also known as Lu AF82422), developed by H. Lundbeck A/S, is an investigational human monoclonal antibody designed to target neurodegenerative processes in multiple system atrophy. The drug specifically binds to extracellular α-synuclein, a pathological protein implicated in MSA, with the aim of preventing its uptake into cells and inhibiting the seeding and spread of toxic protein aggregates across the brain, additionally, through its active Fc region, it may enhance immune-mediated clearance of α-synuclein via microglial activity, thereby potentially slowing disease progression. The drug has received several important designations, including FDA Fast Track designation (2025), Orphan Drug Designation in the US, EU, and Japan, and SAKIGAKE designation in Japan, highlighting its potential to address a significant unmet medical need. Currently, amlenetug is in Phase III clinical development, being evaluated in the global MASCOT trial (NCT06706622), a randomized, double-blind, placebo-controlled study assessing its efficacy, safety, and tolerability in patients with MSA, with dosing administered via intravenous infusion approximately every four weeks.
ATH434, developed by Alterity Therapeutics, is an investigational oral small-molecule therapeutic designed to treat neurodegenerative diseases such as multiple system atrophy (MSA). The drug acts as an iron chaperone, targeting pathological processes by redistributing excess iron in the brain and inhibiting α-synuclein aggregation, which is a key driver of neurodegeneration in MSA, ATH434 aims to protect neurons and slow disease progression. ATH434 is being developed primarily for MSA, a rare and rapidly progressive neurodegenerative disorder with significant unmet medical need. The drug has received Orphan Drug Designation from the U.S. FDA and the European Commission, as well as FDA Fast Track designation, underscoring its potential clinical importance. Clinically, ATH434 has completed Phase II trials (ATH434-201/202), and based on positive data, the program is advancing toward Phase III development, positioning it as a late-stage asset in Alterity’s pipeline.
hOMSC300, developed by Cytora Ltd., is an investigational allogeneic, off-the-shelf cell therapy, a unique stem cell population derived from the neural crest with properties of neural, mesenchymal, and regenerative cells. These cells exhibit a dual mechanism of action involving cell replacement and paracrine trophic effects, enabling neuroprotection, regeneration, and modulation of neuroinflammation, which are key pathological processes in neurodegenerative diseases. The therapy is being developed for multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder affecting autonomic and motor functions, and aims to act as a disease-modifying treatment by slowing disease progression and preserving neuronal function. From a clinical development perspective, Cytora’s pipeline clearly indicates that hOMSC300 is currently in Phase I clinical studies for MSA, with ongoing trials evaluating safety and preliminary efficacy following intrathecal administration.
AB-1005 is an investigational gene therapy developed by AskBio, a wholly owned subsidiary of Bayer AG. The therapy is based on an adeno-associated viral vector serotype 2 (AAV2) designed to deliver the gene encoding glial cell line-derived neurotrophic factor (GDNF) directly into the brain. Mechanistically, AB-1005 enables sustained local production of GDNF within targeted brain regions, which is intended to support the survival and function of dopaminergic neurons and enhance dopamine signaling, thereby addressing the underlying neurodegeneration. The therapy is currently being investigated in the Phase I stage of its development for the treatment of Multiple System Atrophy – parkinsonian type (MSA-P).
If you’re tracking ongoing Multiple System Atrophy Clinical trials, this press release is a must-read @ Multiple System Atrophy Treatment Drugs
The Multiple System Atrophy Pipeline report provides insights into:-
Multiple System Atrophy Companies
Cytora Ltd., Alterity Therapeutics, H. Lundbeck A/S, AskBio, Corestemchemon, Inc., Tiziana Life Sciences Ltd., Kainos Medicine Inc., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., ProMIS Neurosciences, Inc., Ionis Pharmaceuticals, Inc., and Yoda Therapeutics Inc. andothers.
Multiple System Atrophy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as,
Multiple System Atrophy Products have been categorized under various Molecule types such as,
From emerging drug candidates to competitive intelligence, the Multiple System Atrophy Pipeline Report @ Multiple System Atrophy Market Drivers and Barriers, and Future Perspectives
Scope of the Multiple System Atrophy Pipeline Report
Stay ahead in Healthcare Research – discover what’s next for the Multiple System Atrophy Treatment landscape in this detailed analysis @ Multiple System Atrophy Emerging Drugs and Major Players
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight
